JP2024514277A - 単一ドメインｐｄ－ｌ１抗体 - Google Patents

単一ドメインｐｄ－ｌ１抗体 Download PDF

Info

Publication number
JP2024514277A
JP2024514277A JP2023565368A JP2023565368A JP2024514277A JP 2024514277 A JP2024514277 A JP 2024514277A JP 2023565368 A JP2023565368 A JP 2023565368A JP 2023565368 A JP2023565368 A JP 2023565368A JP 2024514277 A JP2024514277 A JP 2024514277A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514277A5 (https=
Inventor
ウェンチン ジアン，
ヤン リウ，
ハイジュアン グ，
フェイフェイ ツイ，
ジェンイー ワン，
ビンシー グオ，
Original Assignee
アイ－エムエービー バイオファーマ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイ－エムエービー バイオファーマ カンパニー リミテッド filed Critical アイ－エムエービー バイオファーマ カンパニー リミテッド
Publication of JP2024514277A publication Critical patent/JP2024514277A/ja
Publication of JP2024514277A5 publication Critical patent/JP2024514277A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023565368A 2021-04-26 2022-04-26 単一ドメインｐｄ－ｌ１抗体 Pending JP2024514277A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2021090058 2021-04-26
CNPCT/CN2021/090058 2021-04-26
CN2021090046 2021-04-26
CNPCT/CN2021/090049 2021-04-26
CNPCT/CN2021/090046 2021-04-26
CN2021090049 2021-04-26
PCT/CN2022/089388 WO2022228445A1 (en) 2021-04-26 2022-04-26 Single domain pd-l1 antibodies

Publications (2)

Publication Number Publication Date
JP2024514277A true JP2024514277A (ja) 2024-03-29
JP2024514277A5 JP2024514277A5 (https=) 2025-05-20

Family

ID=83847760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565368A Pending JP2024514277A (ja) 2021-04-26 2022-04-26 単一ドメインｐｄ－ｌ１抗体

Country Status (5)

Country Link
US (1) US20240209093A1 (https=)
EP (1) EP4330287A4 (https=)
JP (1) JP2024514277A (https=)
CN (1) CN117098780A (https=)
WO (1) WO2022228445A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925947B (zh) * 2022-09-27 2023-08-22 上海百英生物科技股份有限公司 一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟
WO2024104373A1 (en) * 2022-11-15 2024-05-23 I-Mab Biopharma Co., Ltd. Anti-pd-l1 nanobodies
WO2024261338A1 (en) * 2023-06-22 2024-12-26 Ablynx Nv Immunoglobulin single variable domains targeting pd-l1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112142842A (zh) * 2019-06-27 2020-12-29 启愈生物技术(上海)有限公司 抗PD-L1纳米抗体及其Fc融合蛋白和应用
WO2021048725A1 (en) * 2019-09-12 2021-03-18 Biotheus Inc. Anti-pd-l1 single-domain antibody and derivatives and use thereof
CN112552412A (zh) * 2019-12-05 2021-03-26 屈向东 一种包含TGF-β抑制剂、VEGF抑制剂和抗PDL1抗体的三功能融合蛋白

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377497B2 (en) * 2017-01-23 2022-07-05 Suzhou Alphamab Co., Ltd. PD-L1 binding polypeptide or composite
EP3816186A4 (en) * 2018-06-29 2022-04-06 Suzhou Smartnuclide Biopharmaceutical Co., Ltd. PD-L1 BINDING POLYPEPTIDES AND USE THEREOF
TWI793395B (zh) * 2019-01-25 2023-02-21 大陸商信達生物製藥（蘇州）有限公司 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
CN112409483B (zh) * 2019-08-22 2024-08-27 浙江道尔生物科技有限公司 抗pd-l1纳米抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112142842A (zh) * 2019-06-27 2020-12-29 启愈生物技术(上海)有限公司 抗PD-L1纳米抗体及其Fc融合蛋白和应用
WO2021048725A1 (en) * 2019-09-12 2021-03-18 Biotheus Inc. Anti-pd-l1 single-domain antibody and derivatives and use thereof
CN112552412A (zh) * 2019-12-05 2021-03-26 屈向东 一种包含TGF-β抑制剂、VEGF抑制剂和抗PDL1抗体的三功能融合蛋白

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MA LINLIN ET AL.: "A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 531, JPN6026002449, 2020, pages 144 - 151, ISSN: 0005778930 *

Also Published As

Publication number Publication date
CN117098780A (zh) 2023-11-21
EP4330287A4 (en) 2025-03-19
EP4330287A1 (en) 2024-03-06
US20240209093A1 (en) 2024-06-27
WO2022228445A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
US11365255B2 (en) PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
JP6983371B2 (ja) 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
US20210363266A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
KR20210003295A (ko) 항-b7-h3 항체 및 그 용도
JP7257971B2 (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
CA3170025A1 (en) Pvrig binding protein and its medical uses
JP2021513331A (ja) 抗ｂ７−ｈ４抗体、その抗原結合断片及びその医薬用途
CA3087105A1 (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
US20240209093A1 (en) Single domain pd-l1 antibodies
TWI685504B (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途
CN112243443A (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
CN116199778A (zh) 抗4-1bb抗体及其用途
CN108473586B (zh) 抗cd27抗体、其抗原结合片段及其医药用途
WO2024104373A1 (en) Anti-pd-l1 nanobodies
AU2022279173B9 (en) Anti-pd-1 polypeptides and their use
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
HK40036076B (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof
HK40036076A (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof
TW202221038A (zh) 抗ｔｒｏｐ－２抗體、其抗原結合片段或其突變體、及其醫藥用途
NZ736142A (en) Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
HK1213910B (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
NZ721624B2 (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260422